ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.

Sec. Clinical Microbiology

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1537182

This article is part of the Research TopicModulation of Pulmonary Immunity and Function by Bacterial and Host MetabolitesView all 6 articles

Respiratory microbiome and metabolome features associate disease severity and the need of doxycycline treatment in children with macrolide-resistant Mycoplasma pneumoniae-mediated pneumonia

Provisionally accepted
Wei-Chao LiaoWei-Chao Liao1Shiao-Wen LiShiao-Wen Li2En-Wei HsingEn-Wei Hsing3Yi-Yin ChenYi-Yin Chen3Ian Yi-Feng ChangIan Yi-Feng Chang1Yin-Cheng ChenYin-Cheng Chen4Yi-Jiun PanYi-Jiun Pan5Yu-Chia HsiehYu-Chia Hsieh3*
  • 1Chang Gung University, Taoyuan, Taichung County, Taiwan
  • 2National University of Kaohsiung, Kaohsiung, Taiwan
  • 3Chang Gung Memorial Hospital, Taipei, Taiwan
  • 4Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taipei County, Taiwan
  • 5China Medical University (Taiwan), Taichung, Taiwan

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Solobacterium moorei were inversely correlated with disease severity. We assumed that metabolites of divergent microbiomes were related to MRMP development. We identified 15 discriminative amino-acids and fatty-acid-related metabolites in two groups. F. periodonticum abundance was negatively associated with an inflammatory metabolite: a platelet activating factor. Fusobacterium and Oribacterium were related to LysoPE(18:1(9Z)/0:0) and LysoPC(18:1(9Z)) decreases.Microbiota dysbiosis with dysregulated inflammatory glycerolphospholipid-related metabolites were related to disease severity and the need of doxycycline treatment in children with MRMP-mediated pneumonia. Anaerobic bacteria metabolites and metabolic pathway could be beneficial therapeutic targets against M. pneumoniae infection.

Keywords: Mycoplasma pneumoniae, Pneumonia, Respiratory, microbiome, Metabolome, Disease severity Macrolide-resistant Mycoplasma pneumoniae, Disease Severity

Received: 30 Nov 2024; Accepted: 10 Jun 2025.

Copyright: © 2025 Liao, Li, Hsing, Chen, Chang, Chen, Pan and Hsieh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yu-Chia Hsieh, Chang Gung Memorial Hospital, Taipei, Taiwan

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material